TLR9 agonists contribute to remodeling of the lung TME, leading to the formation of tertiary lymphoid structures near the tumor, CD8+ T-cell infiltration of the tumor, DC expansion, and antibody production. This evidence concerns the gene TLR9 and neoplasm.